ESMO 2022: COSMIC-313 Trial of Triplet Therapy in Advanced Renal Cell Carcinoma
Posted: 10/13/2022 | By: Kayci Reyer

The COSMIC-313 trial tested two different triplet therapy regimens in patients with advanced renal cell carcinoma. Choueiri et al presented results from the study during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA8).

Question 1 of 5

The COSMIC-313 trial included previously untreated patients with renal cell carcinoma of ___ risk.

Choose 1